| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| BDMDBaird Medical Investment Holdings Limited | 45.91M | 1.25 | 2.55 | 17.74% | 33.62% | 33% | 0.53 | |
| IVFINVO Fertility, Inc. | 12.29M | 0.81 | -0.03 | 116.25% | -417.01% | -495.09% | 0.78 | |
| AEMDAethlon Medical, Inc. | 2.64M | 2.71 | -0.03 | -0.2% | 0.13 | |||
| HYPDHyperion DeFi, Inc. | 27.38M | 3.35 | -0.06 | 14.14% | -73.86% | -36.05% | ||
| NAOVNanoVibronix, Inc. | 1.59M | 1.46 | -0.11 | 12.05% | -133.04% | -8.41% | 0.19 | |
| ALURAllurion Technologies Inc. | 23.21M | 1.89 | -0.16 | -39.94% | -251.56% | |||
| RBOTVicarious Surgical Inc. | 18.48M | 2.86 | -0.27 | -380.42% | 0.30 | |||
| TELATELA Bio, Inc. | 44.09M | 0.99 | -0.74 | 18.56% | -50.61% | -25.05% | 1.51 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 6.17M | 7.72M | 34.47M | 75.01M | 136.19M | 224.5M |
| Revenue Growth % | - | 0.25% | 3.47% | 1.18% | 0.82% | 0.65% |
| Cost of Goods Sold | 8.05M | 8.97M | 18.61M | 37.93M | 65.14M | 87.4M |
| COGS % of Revenue | 1.31% | 1.16% | 0.54% | 0.51% | 0.48% | 0.39% |
| Gross Profit | -1.89M | -1.25M | 15.87M | 37.09M | 71.05M | 137.1M |
| Gross Margin % | -0.31% | -0.16% | 0.46% | 0.49% | 0.52% | 0.61% |
| Gross Profit Growth % | - | 0.33% | 13.64% | 1.34% | 0.92% | 0.93% |
| Operating Expenses | 41.66M | 46.55M | 70.03M | 117.81M | 180.22M | 233.71M |
| OpEx % of Revenue | 6.75% | 6.03% | 2.03% | 1.57% | 1.32% | 1.04% |
| Selling, General & Admin | 28.52M | 30.27M | 51.04M | 88.83M | 131.77M | 171.41M |
| SG&A % of Revenue | 4.62% | 3.92% | 1.48% | 1.18% | 0.97% | 0.76% |
| Research & Development | 13.15M | 16.27M | 18.99M | 28.98M | 48.45M | 62.3M |
| R&D % of Revenue | 2.13% | 2.11% | 0.55% | 0.39% | 0.36% | 0.28% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -43.55M | -47.8M | -54.16M | -80.72M | -109.17M | -96.61M |
| Operating Margin % | -7.06% | -6.19% | -1.57% | -1.08% | -0.8% | -0.43% |
| Operating Income Growth % | - | -0.1% | -0.13% | -0.49% | -0.35% | 0.12% |
| EBITDA | -42.06M | -44.94M | -50.84M | -77.88M | -105.36M | -91.38M |
| EBITDA Margin % | -6.82% | -5.82% | -1.47% | -1.04% | -0.77% | -0.41% |
| EBITDA Growth % | - | -0.07% | -0.13% | -0.53% | -0.35% | 0.13% |
| D&A (Non-Cash Add-back) | 1.49M | 2.86M | 3.32M | 2.84M | 3.81M | 5.23M |
| EBIT | -41.25M | -47.76M | -54.04M | -81.97M | -101.9M | -87.23M |
| Net Interest Income | 425K | -5.08M | -5.73M | -2.69M | 3.56M | 6.71M |
| Interest Income | 1.15M | 184K | 76K | 2.5M | 7.55M | 10.89M |
| Interest Expense | 724K | 5.26M | 5.81M | 5.18M | 4M | 4.18M |
| Other Income/Expense | 1.57M | -5.22M | -5.69M | -6.43M | 3.27M | 5.2M |
| Pretax Income | -41.98M | -53.02M | -59.85M | -87.15M | -105.9M | -91.41M |
| Pretax Margin % | -6.8% | -6.87% | -1.74% | -1.16% | -0.78% | -0.41% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -41.98M | -53.02M | -59.85M | -87.15M | -105.9M | -91.41M |
| Net Margin % | -6.8% | -6.87% | -1.74% | -1.16% | -0.78% | -0.41% |
| Net Income Growth % | - | -0.26% | -0.13% | -0.46% | -0.22% | 0.14% |
| Net Income (Continuing) | -41.98M | -53.02M | -59.85M | -87.15M | -105.9M | -91.41M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.25 | -1.51 | -3.63 | -1.96 | -2.24 | -1.75 |
| EPS Growth % | - | -0.21% | -1.4% | 0.46% | -0.14% | 0.22% |
| EPS (Basic) | -1.25 | -1.51 | -3.63 | -1.96 | -2.24 | -1.75 |
| Diluted Shares Outstanding | 33.59M | 35.14M | 16.48M | 44.4M | 47.26M | 52.13M |
| Basic Shares Outstanding | 33.59M | 35.14M | 16.48M | 44.4M | 47.26M | 52.13M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 50.36M | 109.9M | 326.17M | 272.63M | 350.57M | 481.84M |
| Cash & Short-Term Investments | 42.02M | 100.13M | 304.32M | 222.64M | 257.22M | 333.73M |
| Cash Only | 42.02M | 100.13M | 304.32M | 222.64M | 257.22M | 333.73M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.1M | 1.55M | 4.46M | 15.27M | 48.38M | 83.5M |
| Days Sales Outstanding | 65.02 | 73.26 | 47.26 | 74.31 | 129.65 | 135.75 |
| Inventory | 6.69M | 7.48M | 13.15M | 28.54M | 39.76M | 56.17M |
| Days Inventory Outstanding | 303 | 304.18 | 257.88 | 274.68 | 222.76 | 234.57 |
| Other Current Assets | 0 | 0 | 3.41M | 6.17M | 5.21M | 8.45M |
| Total Non-Current Assets | 11.64M | 16.07M | 10.85M | 36.7M | 54.15M | 52.17M |
| Property, Plant & Equipment | 8.27M | 12.91M | 8.32M | 32.14M | 48.99M | 45.65M |
| Fixed Asset Turnover | 0.75x | 0.60x | 4.14x | 2.33x | 2.78x | 4.92x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.29M | 2.02M | 1.75M | 1.48M | 1.2M | 932K |
| Long-Term Investments | 691K | 777K | 777K | 3.04M | 3.04M | 3.04M |
| Other Non-Current Assets | 378K | 356K | 0 | 51K | 919K | 2.56M |
| Total Assets | 61.99M | 125.97M | 337.02M | 309.33M | 404.72M | 534.02M |
| Asset Turnover | 0.10x | 0.06x | 0.10x | 0.24x | 0.34x | 0.42x |
| Asset Growth % | - | 1.03% | 1.68% | -0.08% | 0.31% | 0.32% |
| Total Current Liabilities | 6.79M | 14.53M | 16.24M | 35.29M | 45.93M | 53.13M |
| Accounts Payable | 1.44M | 1.24M | 2.03M | 9.39M | 13.5M | 10.03M |
| Days Payables Outstanding | 65.44 | 50.45 | 39.8 | 90.37 | 75.64 | 41.9 |
| Short-Term Debt | 0 | 6.26M | 2.1M | 2.13M | 1.68M | 1.91M |
| Deferred Revenue (Current) | 106K | 233K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 2.9M | 2.15M | 4.61M | 7.47M | 8.2M | 10.09M |
| Current Ratio | 7.42x | 7.57x | 20.08x | 7.73x | 7.63x | 9.07x |
| Quick Ratio | 6.43x | 7.05x | 19.27x | 6.92x | 6.77x | 8.01x |
| Cash Conversion Cycle | 302.59 | 327 | 265.35 | 258.61 | 276.77 | 328.43 |
| Total Non-Current Liabilities | 25.97M | 50.48M | 53.69M | 76.97M | 78.04M | 78.66M |
| Long-Term Debt | 23.22M | 44.41M | 50M | 51.21M | 51.34M | 51.47M |
| Capital Lease Obligations | 0 | 4.1M | 1.99M | 23.98M | 26.18M | 26.87M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.75M | 1.98M | 1.7M | 1.78M | 517K | 324K |
| Total Liabilities | 32.76M | 65.01M | 69.93M | 112.26M | 123.97M | 131.8M |
| Total Debt | 23.22M | 54.76M | 54.1M | 77.32M | 79.2M | 80.25M |
| Net Debt | -18.8M | -45.37M | -250.22M | -145.32M | -178.02M | -253.47M |
| Debt / Equity | 0.79x | 0.90x | 0.20x | 0.39x | 0.28x | 0.20x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -60.15x | -9.09x | -9.32x | -15.57x | -27.33x | -23.09x |
| Total Equity | 29.23M | 60.96M | 267.09M | 197.07M | 280.75M | 402.22M |
| Equity Growth % | - | 1.09% | 3.38% | -0.26% | 0.42% | 0.43% |
| Book Value per Share | 0.87 | 1.73 | 16.21 | 4.44 | 5.94 | 7.72 |
| Total Shareholders' Equity | 29.23M | 60.96M | 267.09M | 197.07M | 280.75M | 402.22M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -148.65M | -201.67M | -261.52M | -348.68M | -454.57M | -545.99M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4K | -14K | -54K | -6K | 84K | 114K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -43.82M | -48.34M | -57.33M | -80.38M | -108M | -99.21M |
| Operating CF Margin % | -7.1% | -6.26% | -1.66% | -1.07% | -0.79% | -0.44% |
| Operating CF Growth % | - | -0.1% | -0.19% | -0.4% | -0.34% | 0.08% |
| Net Income | -41.98M | -53.02M | -59.85M | -87.15M | -105.9M | -91.41M |
| Depreciation & Amortization | 1.49M | 2.86M | 3.32M | 2.84M | 3.81M | 5.23M |
| Stock-Based Compensation | 1.99M | 2.17M | 3.8M | 10.34M | 19.13M | 31.84M |
| Deferred Taxes | 0 | 0 | 451K | 0 | 0 | 0 |
| Other Non-Cash Items | -1.8M | 126K | -345K | 5.08M | 1.11M | 2.45M |
| Working Capital Changes | -3.53M | -483K | -4.71M | -11.49M | -26.16M | -47.33M |
| Change in Receivables | 522K | -511K | -2.91M | -10.81M | -33.1M | -35.96M |
| Change in Inventory | -5.07M | -3.1M | -6.12M | -15.25M | -9.75M | -17.23M |
| Change in Payables | -260K | -205K | 812K | 3.96M | 5.79M | -2.15M |
| Cash from Investing | 43.15M | -233K | -592K | -2.65M | -25.21M | -4.41M |
| Capital Expenditures | -7.61M | -233K | -592K | -2.65M | -25.21M | -4.41M |
| CapEx % of Revenue | 1.23% | 0.03% | 0.02% | 0.04% | 0.19% | 0.02% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 26.53M | 106.77M | 262.12M | 3.61M | 167.79M | 180.13M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 1.99M | 5.6M | 5.04M | 2.42M | 6.09M | 15.6M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -51.43M | -48.58M | -57.93M | -83.03M | -133.21M | -103.62M |
| FCF Margin % | -8.34% | -6.29% | -1.68% | -1.11% | -0.98% | -0.46% |
| FCF Growth % | - | 0.06% | -0.19% | -0.43% | -0.6% | 0.22% |
| FCF per Share | -1.53 | -1.38 | -3.51 | -1.87 | -2.82 | -1.99 |
| FCF Conversion (FCF/Net Income) | 1.04x | 0.91x | 0.96x | 0.92x | 1.02x | 1.09x |
| Interest Paid | 397K | 3.97M | 0 | 4.29M | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -143.6% | -117.57% | -36.49% | -37.55% | -44.32% | -26.77% |
| Return on Invested Capital (ROIC) | - | -275.51% | -250.27% | -176.45% | -106% | -57.63% |
| Gross Margin | -30.56% | -16.26% | 46.02% | 49.44% | 52.17% | 61.07% |
| Net Margin | -680.42% | -687.04% | -173.62% | -116.18% | -77.76% | -40.72% |
| Debt / Equity | 0.79x | 0.90x | 0.20x | 0.39x | 0.28x | 0.20x |
| Interest Coverage | -60.15x | -9.09x | -9.32x | -15.57x | -27.33x | -23.09x |
| FCF Conversion | 1.04x | 0.91x | 0.96x | 0.92x | 1.02x | 1.09x |
| Revenue Growth | - | 25.09% | 346.72% | 117.6% | 81.55% | 64.84% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| UNITED STATES | 19.38M | 36.53M | 124.3M | 200.47M |
| UNITED STATES Growth | - | 88.53% | 240.29% | 61.28% |
| Outside the United States | 2.49M | 3.2M | 11.89M | 24.03M |
| Outside the United States Growth | - | 28.40% | 271.57% | 102.00% |
PROCEPT BioRobotics Corporation (PRCT) reported $299.9M in revenue for fiscal year 2024. This represents a 4762% increase from $6.2M in 2019.
PROCEPT BioRobotics Corporation (PRCT) grew revenue by 64.8% over the past year. This is strong growth.
PROCEPT BioRobotics Corporation (PRCT) reported a net loss of $84.6M for fiscal year 2024.
PROCEPT BioRobotics Corporation (PRCT) has a return on equity (ROE) of -26.8%. Negative ROE indicates the company is unprofitable.
PROCEPT BioRobotics Corporation (PRCT) had negative free cash flow of $79.7M in fiscal year 2024, likely due to heavy capital investments.